Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases
Background: Cardiometabolic morbidity and medications, specifically Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), have been linked with adverse outcomes from coronavirus disease 2019 (COVID-19). This study aims to investigate, factors associated with COVID...
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Frontiers Media S.A.
2020-07-01
|
| シリーズ: | Frontiers in Cardiovascular Medicine |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/article/10.3389/fcvm.2020.00138/full |